Publications and communications of Yvette Habraken

Lemaitre, F., Chakrama, F., O'Grady, T., Peulen, O., Rademaker, G., Deward, A., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F., & Habraken, Y. (30 May 2023). The transcription factor c-Jun mediates specific reprogramming of pre-mRNA splicing during platinum-based therapy via RBM39 [Poster presentation]. 28th Annual International Conference of the RNA society RNA 2023, Singapore.

Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F.* , & Habraken, Y.*. (02 February 2023). The transcription factor c-Jun mediates specific reprogramming of pre-mRNA splicing during platinum-based therapy via RBM39 [Poster presentation]. séminaire des chercheurs Télévie 2023.
* These authors have contributed equally to this work.

Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Peulen, O., Rademaker, G., Deward, A., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F.* , & Habraken, Y.*. (09 December 2022). The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress. Nucleic Acids Research, 50 (22), 12768 - 12789. doi:10.1093/nar/gkac1130
* These authors have contributed equally to this work.

Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F.* , & Habraken, Y.*. (09 September 2022). The transcription factor c-Jun inhibits RBM39 to reprogram mRNA splicing during genotoxic stress [Poster presentation]. Interuniversity PhD student day.
* These authors have contributed equally to this work.

Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Dequiedt, F.* , & Habraken, Y.*. (08 April 2022). c-Jun directly controls spliceosome specificity through RBM39 binding in response to genotoxic chemotherapy [Poster presentation]. séminaire des chercheurs Télévie 2022.
* These authors have contributed equally to this work.

Lemaitre, F.* , Chakrama, F.* , Dequiedt, F.* , & Habraken, Y.*. (17 March 2022). c-Jun directly controls spliceosome specificity through RBM39 binding in response to genotoxic chemotherapy [Poster presentation]. Multiple facets of RNA in development and disease.
* These authors have contributed equally to this work.

Lemaitre, F., Chakrama, F., O'Grady, T., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F., & Habraken, Y. (March 2022). The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress [Poster presentation]. THE MULTIPLE FACETS OF RNA IN DEVELOPMENT AND DISEASE, Nice, France.

Gamelas, S., Moura, N., Habraken, Y., Piette, J., Neves, M., & Faustino, M. (September 2021). Tetracationic porphyrin derivatives against human breast cancer. Journal of Photochemistry and Photobiology B: Biology, 222, 112258. doi:10.1016/j.jphotobiol.2021.112258

Habraken, Y. (July 2021). Large scale regulation of the spliceosome through direct binding of c-JUN to RBM39 following genotoxic stress [Paper presentation]. 4th International Caparica Conference in SPLICING 2021, Caparica, Portugal.

Lemaitre, F., Chakrama, F., Dequiedt, F., Chabot, B., Klinck, R., Colige, A., Piette, J., Lambert, C., & Habraken, Y. (15 April 2021). c-Jun and RBM39 co-regulate alternative splicing induced by chemotherapy compounds [Poster presentation]. Joint Course on Post-Transcriptional Gene Regulation and Genome Instability, Paris, France.

Chakramah, F., Lemaitre, F., Dequiedt, F., Chabot, B., Klink, R., Colige, A., Piette, J., Lambert, C., & Habraken, Y. (July 2020). c-Jun and RBM39 co-regulate alternative splicing induced by chemotherapy compounds [Poster presentation]. Third international Caparica conference in splicing, Caparica, Portugal.

Shostak, K., Jiang, Z., CHARLOTEAUX, B., Mayer, A., Habraken, Y., Tharun, L., Klein, S., Xu, X., Duong, H. Q., Vislovukh, A., Close, P., Florin, A., Rambow, F., Marine, J.-C., Büttner, R., & Chariot, A. (09 March 2020). The X-linked trichothiodystrophy-causing gene RNF113A links the spliceosome to cell survival upon DNA damage. Nature Communications, 11 (1). doi:10.1038/s41467-020-15003-7

Gianfrancesco, M., Dehairs, J., L'homme, L., Herinckxe, G., Esser, N., Jansen, O., Habraken, Y., Lassence, C., Swinnen, J., Rider, M., Piette, J., PAQUOT, N., & Legrand, S. (April 2019). Saturated fatty acids induce NLRP3 activation in human macrophages through K+ efflux resulting from phospholipid saturation and Na, K-ATPase disruption. BBA - Molecular and Cell Biology of Lipids, 1864, 1017–1030. doi:10.1016/j.bbalip.2019.04.001

Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2019). Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis. doi:10.1038/s41389-019-0130-6
* These authors have contributed equally to this work.

Chakrama, F., Gabriel, M., Deward, A., Lassence, C., Colige, A., Lambert, C., & Habraken, Y. (September 2018). Alternative splicing induced by Cisplatin: effect on the shape of mitochondria [Poster presentation]. Joint meeting GIGA-Cancer Day 2018 / EDT-Cancerology.

Trussart, C., Pirlot, C., Di Valentin, E., Piette, J., & Habraken, Y. (2018). Melanoma antigen-D2 controls cell cycle progression and modulates the DNA damage response. Biochemical Pharmacology. doi:10.1016/j.bcp.2018.01.035

Chakrama, F., Lambert, C., Gabriel, M., Deward, A., Lassence, C., Colige, A., & Habraken, Y. (October 2017). Alternative splicing induced by cisplatin : Effect on mitochondria shape [Poster presentation]. Forty Years of mRNA Splicing: From Discovery to Therapeutics meeting, New-York, United States.

Trussart, C., Pirlot, C., Piette, J., & Habraken, Y. (11 May 2017). MAGED2 function as cell cycle regulator after a genotoxic stress [Poster presentation]. PhD DAY.

Gabriel, M., Garbacki, N., Chakrama, F., Habraken, Y., Colige, A., & Lambert, C. (May 2017). Chemotherapy regulates the expression of alternative transcripts: relationship to the new hallmarks of cancer and therapeutic efficacy [Poster presentation]. International symposium on the Hallmarks of Cancer: Focus on RNA, Prague, Czechia.

Habraken, Y. (2017). Les dommages à l’ADN et leurs réponses cellulaires [Paper presentation]. Exposé pour la section science et nature de l'université du troisième âge.

Trussart, C., Pirlot, C., Piette, J., & Habraken, Y. (2017). Incidence of MAGED2 on cell cycle after a camptothecin treatment [Poster presentation]. GIGA DAY 2017.

Deward, A., Gabriel, M., Klinck, R., Chabot, B., Figueroa, M., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (11 September 2016). c-Jun regulates altered pre-mRNA splicing in response to cisplatin [Poster presentation]. Splicing 2016, Caparica, Portugal.

Henry, A., Nokin, M.-J., Leroi, N., Lallemand, F., Lambert, J., Goffart, N., RONCARATI, P., BIANCHI, E., Peixoto, P., Blomme, A., Turtoi, A., Peulen, O., Habraken, Y., Scholtes, F., Martinive, P., Delvenne, P., Rogister, B., Castronovo, V., & Bellahcene, A. (2016). New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity. Oncotarget. doi:10.18632/oncotarget.11483

Henry, A., Nokin, M.-J., Leroi, N., LALLEMAND, F., Lambert, J., Goffart, N., Peixoto, P., Blomme, A., BIANCHI, E., Habraken, Y., RONCARATI, P., Peulen, O., SCHOLTES, F., MARTINIVE, P., Rogister, B., Delvenne, P., Turtoi, A., Castronovo, V., & Bellahcene, A. (22 March 2016). Osteopontin predicts radiotherapy response of glioblastoma patients : new role in DNA damage repair [Paper presentation]. 3rd Symposium on small animal precision image-guided radiotherapy, Gand, Belgium.

Deward, A., Gabriel, M., Klinck, R., Chabot, B., Figueroa, M., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (25 January 2016). A c-jun/splicing factors complex triggers altered pre-mRNA splcing in response to cisplatin [Poster presentation]. GIGA DAY Molecular Biology of Disease.

Pirlot, C., Thiry, M., Trussart, C., Di Valentin, E., Piette, J., & Habraken, Y. (2016). Melanoma antigen-D2: a nucleolar protein undergoing delocalization during cell cycle and after cellular stress. Biochimica et Biophysica Acta. Molecular Cell Research, 1853 (3), 581-595. doi:10.1016/j.bbamcr.2015.12.010

Trussart, C., Pirlot, C., Piette, J., & Habraken, Y. (03 December 2015). Melanoma AntiGEn D2 : a new cell cycle regulator of the DNA Damage Response network [Poster presentation]. Séminaire des chercheurs télévie.

Pirlot, C., Thiry, M., Trussart, C., Di Valentin, E., Piette, J., & Habraken, Y. (03 November 2015). Melanoma antigen D2, a substrate of ATM, is a nucleolar protein that shuttles with cell cycle and cellular stress [Poster presentation]. PI3K-like protein kinases, Milan, Italy.

Deward, A., Gabriel, M., Delforge, Y., Chabot, B., Klinck, R., Figueroa, M., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (28 September 2015). c-Jun : a new regulatory element for cisplatin induced alternative splicing [Poster presentation]. Discoble meeting IAP 7/32, Gent, Belgium.

Pirlot, C., Thiry, M., Trussart, C., Piette, J., & Habraken, Y. (28 September 2015). Melanoma AntiGEn D2 : a new nucleolar protein undergoing delocalization during cell cycle and after cellular stress [Poster presentation]. IAP meeting, Gent, Belgium.

Henry, A., Bellahcene, A., Castronovo, V., Peixoto, P., Goffart, N., Lallemand, F., Leroi, N., Peulen, O., MARTINIVE, P., Habraken, Y., Turtoi, A., Rogister, B., & Blomme, A. (Other coll.). (10 September 2015). Osteopontin as a new target in glioblastoma progression and resistance to radiotherapy [Paper presentation]. II International Symposium on clinical and basic investigation in glioblastoma, Toledo, Spain.

Pirlot, C., Thiry, M., Trussart, C., Piette, J., & Habraken, Y. (06 February 2015). Melanoma AntiGEn D2 (MAGED2): a new nucleolar protein undergoing re-localization after cellular stress [Poster presentation]. IAP meeting, Leuven, Belgium.

Trussart, C., Orban, T., Di Valentin, E., Piette, J., & Habraken, Y. (06 February 2015). The phosphorylation of RelA on Ser547 does not modulate NF-kB activation after TNFa treatment like after a genotoxic stress [Poster presentation]. DISCOLBEL meeting in KUL, Louvain, Belgium.

Gabriel, M., Delforge, Y., Deward, A., Habraken, Y., Hennuy, B., Piette, J., Klinck, R., Chabot, B., Lambert, C., & Colige, A. (2015). Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis. BMC Cancer, 15, 227. doi:10.1186/s12885-015-1259-0

Trussart, C., Orban, T., Di Valentin, E., Piette, J., & Habraken, Y. (29 August 2014). Promoter specific regulation of NF-kappaB by RelA phosphorylation on Ser547 [Poster presentation]. Discobel meeting.

Pirlot, C., Piette, J., & Habraken, Y. (January 2014). Melanoma AntiGEn D2 (MAGED2) a new partner of the DNA damage response? [Poster presentation]. Metabolism 2014: Alterations of metabolic pathways as therapeutic targets, Esch-sur-Alzette, Luxembourg.

Trussart, C., Orban, T., Sabatel, H., Di Valentin, E., Piette, J., & Habraken, Y. (January 2014). Promotor specific regulation of NF-kappaB mediated transcription by the phosphorylation of p65 on Ser547 [Poster presentation]. Metabolism 2014: Alterations of metabolic pathways as therapeutic targets, Esh-sur-Alzette, Luxembourg.

Deward, A., Gabriel, M., Delforge, Y., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (November 2013). Study of molecular mechanisms of DNA Damage induced alternative splicing: implications in cancer therapy [Poster presentation]. ICGEEB 2nd Post-EURASNET Symposium "RNA alternative Splicing", Trieste, Italy.

Habraken, Y. (13 November 2012). An additional role for ATM in the control of NF-kappaB activation by DNA double-strand breaks [Paper presentation]. Molecular and Cellular Biology Meeting, Luxembourg, Luxembourg.

Habraken, Y. (11 May 2012). NF-kappaB activation by DNA damage [Paper presentation]. Xème RÉUNION DU GROUPE DE CONTACT FNRS :Oxidative stress and genotoxic response, Mons, Belgium.

Deward, A., Gabriel, M., Delforge, Y., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (2012). Study of camptothecin- and cisplatin-induced alternative splicing events [Poster presentation]. Xème groupe de contact FNRS: oxidative stress and genotoxic responses, Mons, Belgium.

Herfs, M., Hubert, P., POIRRIER, A.-L., Vandevenne, Renoux, V., Habraken, Y., Cataldo, D., Boniver, J., & Delvenne, P. (2012). Proinflammatory Cytokines Induce Bronchial Hyperplasia and Squamous Metaplasia in Smokers: Implications for chronic obstructive pulmonary disease therapy. American Journal of Respiratory Cell and Molecular Biology, 47 (1), 67-79. doi:10.1165/rcmb.2011-0353OC

Lecat, A., Di Valentin, E., Somja, J., Jourdan, S., Fillet, M., Kufer, T., Habraken, Y., Sadzot-Delvaux, C., Louis, E., Delvenne, P., Piette, J., & Legrand-Poels, S. (2012). The c-jun N-terminal Kinase (JNK)-binding Protein (JNKBP1) Acts as a Negative Regulator of NOD2 Protein Signaling by Inhibiting Its Oligomerization Process. Journal of Biological Chemistry, 287 (35), 29213-26. doi:10.1074/jbc.M112.355545

Sabatel, H., Di Valentin, E., Gloire, G., Dequiedt, F., Piette, J., & Habraken, Y. (2012). Phosphorylation of p65(RelA) on Ser547 by ATM represses NF-κB-dependent transcription of specific genes after genotoxic stress. PLoS ONE. doi:10.1371/journal.pone.0038246

Sabatel, H., Pirlot, C., Piette, J., & Habraken, Y. (November 2011). Importance of the PIKKs in NF-kappaB activation by genotoxic stress. Biochemical Pharmacology, 82 (10), 1371-83. doi:10.1016/j.bcp.2011.07.105

Coupienne, I., Bontems, S., Dewaele, M., Rubio, N., Habraken, Y., Fulda, S., Agostinis, P., & Piette, J. (2011). NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochemical Pharmacology. doi:10.1016/j.bcp.2010.12.015

Vandevenne, P., Lebrun, M., El Mjiyad, N., Ote, I., Di Valentin, E., Habraken, Y., Dortu, E., Piette, J., & Sadzot-Delvaux, C. (February 2011). The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS ONE, 9 (2). doi:10.1371/journal.pone.0016870

Sabatel, H., Piette, J., & Habraken, Y. (25 January 2011). Role of MDC1 in NF-kappaB activation by DNA double-strand breaks [Poster presentation]. Cell Signal-OMIC, Luxembourg, Luxembourg.

Habraken, Y., & Piette, J. (08 March 2010). NF-kappaB activation by DNA double strand breaks is MDC1 and 53BP1 dependent [Poster presentation]. Maintenance of genome stability 2010, Jolly, Antigua & Barbuda.

Habraken, Y., & Piette, J. (27 January 2010). NF-kappaB activation by DNA double strand breaks is MDC1 and 53BP1 dependent [Poster presentation]. Inflammation 2010, Luxembourg, Luxembourg.

Ulens, E., Sabatel, H., Piette, J., & Habraken, Y. (27 January 2010). MageD2, a newly identified ATM substrate, regulates the DNA damage induced transcriptional response [Poster presentation]. Inflammation 2010, Luxembourg, Luxembourg.

Habraken, Y., & Piette, J. (30 March 2009). NF-kappaB activation by DNA double strand breaks is MDC1 dependent [Poster presentation]. Systems level understanding of DNA damage responses 3rd US-EU Workshop, Egmond aan Zee, Netherlands.

Habraken, Y., & Piette, J. (08 March 2009). NF-kappaB activation by DNA double strand breaks is MDC1 and 53BP1 dependent [Poster presentation]. Maintenance of genome stability 2010, Jolly, Antigua & Barbuda.

Habraken, Y., & Piette, J. (04 March 2008). The early nuclear steps of Nf-kappaB activation by DNA double strand breaks [Poster presentation]. Maintenance of genome stability 2008, Puerto Vallarta, Mexico.

Mineur, P., Colige, A., Deroanne, C., Dubail, J., Kesteloot, F., Habraken, Y., Noël, A., Voo, S., Waltenberger, J., Lapière, C. M., Nusgens, B., & Lambert, C. (17 December 2007). Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. Journal of Cell Biology, 179 (6), 1261-1273. doi:10.1083/jcb.200703052

Horion, J., Gloire, G., El Mjiyad, N., Quivy, V., Vermeulen, L., Vanden Berghe, W., Haegeman, G., Van Lint, C., Piette, J., & Habraken, Y. (2007). Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappa B activation by delaying IkappaBalpha mRNA resynthesis : comparison with tumor necrosis factor alpha. Journal of Biological Chemistry, 282 (21), 15383. doi:10.1074/jbc.M609166200

Habraken, Y., & Piette, J. (30 October 2006). NF-kappa B activation by double-strand breaks [letter to the editor]. Biochemical Pharmacology, 72 (9), 1132-1141. doi:10.1016/j.bcp.2006.07.015

Horion, J., Quivy, V., Gloire, G., Van Lint, C., Piette, J., & Habraken, Y. (23 March 2006). HDAC inhibitor trichostatin A potentiates pervanadate-induced NF-kappB activtion by delaying ikappaBalpha mRNA resynthesis [Poster presentation]. Keystone symposia NF-kappaB: 20 Years on the Road from Biochemistry to Pathology, Banff, Canada.

Nys, M., Preiser, J.-C., Deby, G., Habraken, Y., Mathy, M., Damas, P., & Lamy, M. (2005). Nitric oxide-related products and myeloperoxidase in bronchoalveolar lavage fluids from patients with ALI activate NF-kappa B in alveolar cells and monocytes. Vascular Pharmacology, 43 (6), 425-33. doi:10.1016/j.vph.2005.08.007

Verrax, J., Cadrobbi, J., Marques, C., Taper, H., Habraken, Y., Piette, J., & Calderon, P. B. (March 2004). Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis, 9 (2), 223-233. doi:10.1023/B:APPT.0000018804.26026.1a

Habraken, Y., & Piette, J. (11 January 2004). Differential involvement of the Mre11/Rad50/NBS (M/R/N) complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray [Poster presentation]. Keystone symposia NF-kappaB : Biology and Pathology, Snowbird, United States.

De Klerck, B., Carpentier, I., Lories, R. J., Habraken, Y., Piette, J., Carmeliet, G., Beyaert, R., Billiau, A., & Matthys, P. (2004). Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b(+) myelopoiesis. Arthritis Research and Therapy, 6 (3), 220-R231. doi:10.1186/ar1167

Mouithys-Mickalad, A., Deby, G., Mathy, M., Habraken, Y., Nys, M., Henrotin, Y., Lamy, M., & Deby, C. (2004). Effects of glucocorticoids on the respiratory burst of Chlamydia-primed THP-1 cells. Biochemical and Biophysical Research Communications, 318 (4), 941-8. doi:10.1016/j.bbrc.2004.04.120

Volanti, C., Gloire, G., Vanderplasschen, A., Jacobs, N., Habraken, Y., & Piette, J. (2004). Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. Oncogene, 23 (53), 8649-8658. doi:10.1038/sj.onc.1207871

Piette, J., Volanti, C., Vantieghem, A., Matroule, J.-Y., Habraken, Y., & Agostinis, P. (15 October 2003). Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers. Biochemical Pharmacology, 66 (8), 1651-1659. doi:10.1016/S0006-2952(03)00539-2

Habraken, Y., Jolois, O., & Piette, J. (04 September 2003). Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappa B activation by camptothecin and X-ray. Oncogene, 22 (38), 6090-6099. doi:10.1038/sj.onc.1206893

Nys, M., Deby, G., Habraken, Y., Legrand-Poels, S., Kohnen, S., Ledoux, D., Canivet, J.-L., Damas, P., & Lamy, M. (2003). Bronchoalveolar lavage fluids of ventilated patients with acute lung injury activate NF-kB in alveolar epithelial cell line: role of reactive oxygen/nitrogen species and cytokines. Nitric Oxide, 9 (1), 33-43. doi:10.1016/j.niox.2003.07.001

Nys, M., Deby-Dupont, G., Habraken, Y., Legrand-Poels, S., Ledoux, D., CANIVET, J.-L., Damas, P., & Lamy, M. (December 2002). Bronchoalveolar lavage fluids of patients with lung injury activate the transcription factor nuclear factor-kappa beta in an alveolar cell line. Clinical Science, 103 (6), 577-585. doi:10.1042/cs1030577

Habraken, Y., & Piette, J. (30 January 2002). Activation of the NF-kappaB transcription factor by Camptothecin [Poster presentation]. CELL SIGNALING, TRANSCRIPTION AND TRANSLATION AS THERAPEUTIC TARGET, Luxembourg, Luxembourg.

Habraken, Y., & Piette, J. (07 January 2002). Activation of the NF-kappaB transcription factor by DNA damage [Poster presentation]. Molecular mechanism of DNA replication and recombination, Snowbird, United States.

Habraken, Y., Piret, B., & Piette, J. (01 September 2001). S Phase Dependence and Involvement of Nf-Kappab Activating Kinase to Nf-Kappab Activation by Camptothecin. Biochemical Pharmacology, 62 (5), 603-16. doi:10.1016/S0006-2952(01)00709-2

Habraken, Y., Piret, B., & Piette, J. (04 July 2001). S phase dependance and involvement of the NF-kappaB activation kinase to NF-kappaB activation by Camptotheci [Poster presentation]. International NF-kappaB symposium, Ghent, Belgium.

Habraken, Y., Piret, B., & Piette, J. (22 February 2000). Activation of the NF-kappaB transcription factor by Camptothecin in HeLa cells [Poster presentation]. NF-kappaB Regulation and Function: From Basic Research to Drug Development (F2), Tahoe City, United States.

Habraken, Y. (1999). DNA repair mechanisms: implication in cancer [Post doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/135380

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (17 April 1998). ATP dependeny assembly of a ternary complex consisting of DNA Mismatch and the yeast Msh2-Msh6 and Mlh1-Pms1 protein complexes. Journal of Biological Chemistry, 273 (16), 9837-41. doi:10.1074/jbc.273.16.9837

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (01 October 1997). Enhancement of MSH2-MSH3-mediated mismatch repair recognition by the yeast MLH1-PMS1 complex. Current Biology, 7 (10), 790-3. doi:10.1016/S0960-9822(06)00337-X

Johnson, R., Kovvali, G., Guzder, S., Amin, N., Holm, C., Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (08 November 1996). Evidence of involvement of yeast proliferating cell nuclear antigen in DNA mismatch repair. Journal of Biological Chemistry, 271 (45), 27897-90. doi:10.1074/jbc.271.45.27987

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (01 October 1996). Transcription factor TFIIH and DNA endonuclease Rad2 constitute yeast nucleotide excision repair factor 3: implications for nucleotide excision repair and Cockayne syndrome. Proceedings of the National Academy of Sciences of the United States of America, 93 (20), 10718-22. doi:10.1073/pnas.93.20.10718

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (01 September 1996). Binding of insertion/deletion DNA mismatches by the heterodimer of yeast mismatch repair protein MSH2 and MSH3. Current Biology, 6 (9), 1185-7. doi:10.1016/S0960-9822(02)70686-6

Guzder, S., Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (02 August 1996). RAD26, the yeast homolog of human Cockayne 's syndrome group B, encodes a DNA dependent ATPase. Journal of Biological Chemistry, 271 (31), 18314-7. doi:10.1074/jbc.271.31.18314

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (15 December 1995). Structure-specific nuclease activity in yeast nucleotide excision repair protein RAD2. Journal of Biological Chemistry, 270 (50), 30194-8. doi:10.1074/jbc.270.50.30194

Guzder, S., Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (02 June 1995). Reconstitution of yeast nucelotide excision repair with purified RAD proteins, replication protein A and transcription factor TFIIH. Journal of Biological Chemistry, 270 (22), 12973-6. doi:10.1074/jbc.270.22.12973

Habraken, Y., Sung, P., Prakash, L., & Prakah, S. (16 December 1994). A conserved 5' to 3' exonuclease activity in yeast and human nucleotide excision repair protein RAD2 and XPG. Journal of Biological Chemistry, 269 (50), 31342-5.

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (06 October 1994). Holliday junction cleavage by yeast Rad1 protein. Nature, 371, 531-4. doi:10.1038/371531a0

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (25 August 1994). Human xeroderman group G gene encodes a DNA endonuclease. Nucleic Acids Research, 22 (16), 3312-6. doi:10.1093/nar/22.16.3312

Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (25 December 1993). Yeast excision repair RAD2 encodes a single-stranded DNA endonuclease. Nature, 366, 365-368. doi:10.1038/366365a0

Habraken, Y., & Laval, F. (March 1993). Increased resistance of the chinese hamster mutant irs1 cells to monofunctionnal alkylating agents by transfection of the E.coli or mammalian N3-methyladenine-DNA glycosylase genes. Mutation Research, 293 (3), 187-195. doi:10.1016/0921-8777(93)90069-S

Ludlum, D., Habraken, Y., Carter, C., & Matijasevic, Z. (1992). The formation and enzymatic repair of DNA modifications caused by haloethylnitrosoureas and related compounds. Nucleic Acids Symposium Series, 105, 25-26.

Habraken, Y., & Laval, F. (15 February 1991). Enhancement of 1,3-bis(2-chloroethyl)-1-nitrosourea resistance by gy gamma-irradiation or drug pretreatment in rat hepatoma cells. Cancer Research, 51 (4), 499-503.

Habraken, Y., Carter, C., Kirk, M., & Ludlum, D. (1991). Release of 7-alkylguanines from N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea-modified DNA by 3 methyladenine DNA glycosylase. Cancer Research, 51, 499-503.

Habraken, Y., Carter, C., Sekiguchi, M., & Ludlum, D. (1991). Release of N2,3-ethanoguanine from haloethylnitrosourea-treated DNA by Escherichia coli 3-methyladenine DNA glycosylase II. Carcinogenesis, 12 (10), 1971-1973. doi:10.1093/carcin/12.10.1971

Laval, J., Lopes, F., Madelmont, J., Godeneche, D., Meyniel, G., Habraken, Y., O'Connor, T., & Boiteux, S. (1991). Excision of imidazole ring-opened N7-hydroxyethylguanine from chloroethylnitrosourea-treated DNA by Escherichia coli formamidopyrimidine-DNA glycolsylase. IARC Scientific Publications, 105, 412-416.

Siew, E., Habraken, Y., & Ludlum, D. (1991). Synthesis of high specificity tritium labelled chloroethylcyclohexylnitrosourea and its application to the study of DNA modification. Journal of the radiolabelled compounds and radiopharmaceuticals, XXIX, 223-230. doi:10.1002/jlcr.2580290212

Habraken, Y., Carter, C., Kirk, M., Riordan, J., & Ludlum, D. (1990). Formation of N2,3-ethanoguanine in DNA after in vitro treatment with the therapeutic agent, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea. Carcinogenesis, 11 (2), 223-228. doi:10.1093/carcin/11.2.223

Young, T. L., Habraken, Y., Ludlum, D., & Santella, R. (1990). Development of monoclonal antibodies recognizing 7-(2-hydroxyethyl)guanine and imidazole ring-opened 7-(2-hydroxyethyl)guanine. Carcinogenesis, 11, 1685-1689. doi:10.1093/carcin/11.10.1685

Habraken, Y., & Ludlum, D. (March 1989). Release of the chloroethyl ethyl sulfide-modified DNA bases by bacterial 3-methyladenine DNA glycosylase I and II. Carcinogenesis, 10 (3), 489-492. doi:10.1093/carcin/10.3.489

Carter, C. A., Habraken, Y., & Ludlum, D. (30 September 1988). Release of 7-alkylguanines from haloethylnitrosourea-treated DNA by E. coli 3-methyladenine-DNA glycosylase II. Biochemical and Biophysical Research Communications, 155 (3), 1261-5. doi:10.1016/S0006-291X(88)81276-2

Habraken, Y., & Verly, W. G. (15 January 1988). Further Purification and Characterization of the DNA 3'-Phosphatase from Rat-Liver Chromatin Which Is Also a Polynucleotide 5'-Hydroxyl Kinase. European Journal of Biochemistry, 171 (1-2), 59-66. doi:10.1111/j.1432-1033.1988.tb13758.x

Habraken, Y., & Verly, W. (24 October 1986). Chromatin 3'-phosphatase /5'OH kinase cannot transfer phosphate from 3' to 5' across a nick in DNA. Nucleic Acids Research, 14 (20), 8103-10. doi:10.1093/nar/14.20.8103

Habraken, Y. (1986). 3' phosphatase chromatinienne et réparation des cassures produites dans l'ADN par les radiations ionisantes [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/135377

Habraken, Y., & Verly, W. (1984). Réparation des cassures induites par les radiations ionisantes et 3'phosphatase chromatinienne. Comptes Rendus des Séances de la Société de Biologie et de ses Filiales, 178 (2), 208-210.

Habraken, Y., & Verly, W. (August 1983). The DNA 3'-phosphatase and 5'-hydroxyl kinase of rat liver chromatin. FEBS Letters, 160 (1,2), 46-50. doi:10.1016/0014-5793(83)80933-8